BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [31] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [32] Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
    Joan Carles
    Isabel Chirivella
    Miguel Ángel Climent
    Enrique Gallardo
    Arancha González del Alba
    José Pablo Maroto
    Begoña Mellado
    Francisco Xavier García del Muro
    Cancer and Metastasis Reviews, 2012, 31 : 3 - 9
  • [33] Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
    Carles, Joan
    Chirivella, Isabel
    Angel Climent, Miguel
    Gallardo, Enrique
    Gonzalez del Alba, Arancha
    Pablo Maroto, Jose
    Mellado, Begona
    Garcia del Muro, Francisco Xavier
    CANCER AND METASTASIS REVIEWS, 2012, 31 : S3 - S9
  • [34] Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Bournakis, E.
    Boutis, A.
    Koutsoukos, K.
    Syrios, J.
    Tzovaras, A.
    Chatzikou, M.
    Michailidi, C.
    Maniadakis, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] First-line treatment ofmetastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J.
    ONKOLOGIE, 2024, 30 (04): : 319 - 328
  • [36] First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
    Fontes-Sousa, Mario
    Calvo, Emiliano
    CANCER TREATMENT REVIEWS, 2022, 105
  • [37] Non-interventional study of first-line therapy in advanced or metastatic renal cell carcinoma
    Rexer, Heidrun
    Wunderlich, Heiko
    Doehn, Christian
    AKTUELLE UROLOGIE, 2024, 55 (03)
  • [38] First-line treatment options in metastatic renal cell cancer
    Kapoor, Anil
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (11-12): : S236 - S238
  • [39] Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC)
    Mueller, L.
    Muench, A.
    Blumenstengel, K.
    Hutzschenreuther, U.
    Busies, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS
    Klijn, S.
    Van de Wetering, G.
    Malcolm, B.
    Dale, P.
    Pompen, M.
    Stevanovic, J.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
12345